Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 22

1.

Distinct physiological, biochemical and morphometric adjustments in the malaria vectors Anopheles gambiae and A. coluzzii as means to survive dry season conditions in Burkina Faso.

Hidalgo K, Montazeau C, Siaussat D, Braman V, Trabalon M, Simard F, Renault D, Dabiré RK, Mouline K.

J Exp Biol. 2018 Mar 21;221(Pt 6). pii: jeb174433. doi: 10.1242/jeb.174433.

PMID:
29378815
2.

Altering Metabolic Profiles of Drugs by Precision Deuteration 2: Discovery of a Deuterated Analog of Ivacaftor with Differentiated Pharmacokinetics for Clinical Development.

Harbeson SL, Morgan AJ, Liu JF, Aslanian AM, Nguyen S, Bridson GW, Brummel CL, Wu L, Tung RD, Pilja L, Braman V, Uttamsingh V.

J Pharmacol Exp Ther. 2017 Aug;362(2):359-367. doi: 10.1124/jpet.117.241497. Epub 2017 Jun 13.

PMID:
28611092
3.

Comparative physiological plasticity to desiccation in distinct populations of the malarial mosquito Anopheles coluzzii.

Hidalgo K, Siaussat D, Braman V, Dabiré KR, Simard F, Mouline K, Renault D.

Parasit Vectors. 2016 Nov 2;9(1):565.

4.

A First-in-Patient, Multicenter, Double-Blind, 2-Arm, Placebo-Controlled, Randomized Safety and Tolerability Study of a Novel Oral Drug Candidate, CTP-499, in Chronic Kidney Disease.

Sabounjian L, Graham P, Wu L, Braman V, Cheng C, Liu J, Shipley J, Neutel J, Dao M.

Clin Pharmacol Drug Dev. 2016 Jul;5(4):314-25. doi: 10.1002/cpdd.241. Epub 2016 Feb 11.

PMID:
27310332
5.

Production of active glycosylation-deficient γ-secretase complex for crystallization studies.

López AR, Dimitrov M, Gerber H, Braman V, Hacker DL, Wurm FM, Fraering PC.

Biotechnol Bioeng. 2015 Dec;112(12):2516-26. doi: 10.1002/bit.25675. Epub 2015 Jul 14.

PMID:
26059427
6.

Quantitative analyses of CTP-499 and five major metabolites by core-structure analysis.

Tang X, Bridson G, Ke J, Wu L, Erol H, Graham P, Lin CH, Braman V, Zhao H, Liu JF, Lin ZJ, Cheng C.

J Chromatogr B Analyt Technol Biomed Life Sci. 2014 Jul 15;963:1-9. doi: 10.1016/j.jchromb.2014.05.043. Epub 2014 May 28.

PMID:
24927417
7.

Variable expression levels detected in the Drosophila effectors of piRNA biogenesis.

Fablet M, Akkouche A, Braman V, Vieira C.

Gene. 2014 Mar 1;537(1):149-53. doi: 10.1016/j.gene.2013.11.095. Epub 2013 Dec 18.

8.

Revealing the metabolic sites of atazanavir in human by parallel administrations of D-atazanavir analogs.

Cheng C, Vedananda S, Wu L, Harbeson S, Braman V, Tung R.

J Mass Spectrom. 2013 Sep;48(9):1019-31. doi: 10.1002/jms.3247.

PMID:
24078243
9.

Maternally deposited germline piRNAs silence the tirant retrotransposon in somatic cells.

Akkouche A, Grentzinger T, Fablet M, Armenise C, Burlet N, Braman V, Chambeyron S, Vieira C.

EMBO Rep. 2013 May;14(5):458-64. doi: 10.1038/embor.2013.38. Epub 2013 Apr 5.

10.

A Randomized Phase I Evaluation of CTP-499, a Novel Deuterium-Containing Drug Candidate for Diabetic Nephropathy.

Braman V, Graham P, Cheng C, Turnquist D, Harnett M, Sabounjian L, Shipley J.

Clin Pharmacol Drug Dev. 2013 Jan;2(1):53-66. doi: 10.1002/cpdd.3. Epub 2013 Feb 21.

PMID:
27121560
11.

Relationship of quality of life scores with baseline characteristics and outcomes in the African-American heart failure trial.

Carson P, Tam SW, Ghali JK, Archambault WT, Taylor A, Cohn JN, Braman VM, Worcel M, Anand IS.

J Card Fail. 2009 Dec;15(10):835-42. doi: 10.1016/j.cardfail.2009.05.016.

PMID:
19944359
12.

Evidence for the continued safety and tolerability of fixed-dose isosorbide dinitrate/hydralazine in patients with chronic heart failure (the extension to African-American Heart Failure Trial).

Yancy CW, Ghali JK, Braman VM, Sabolinski ML, Worcel M, Archambault WT, Franciosa JA.

Am J Cardiol. 2007 Aug 15;100(4):684-9. Epub 2007 Jun 26.

PMID:
17697829
13.

Safety and clinical effects of topical histatin gels in humans with experimental gingivitis.

Paquette DW, Simpson DM, Friden P, Braman V, Williams RC.

J Clin Periodontol. 2002 Dec;29(12):1051-8.

PMID:
12492903
14.

Clinical and microbial evaluation of a histatin-containing mouthrinse in humans with experimental gingivitis: a phase-2 multi-center study.

Van Dyke T, Paquette D, Grossi S, Braman V, Massaro J, D'Agostino R, Dibart S, Friden P.

J Clin Periodontol. 2002 Feb;29(2):168-76.

PMID:
11895545
15.

Phase 1 evaluation of a local delivery device releasing silver ions in periodontal pockets: safety, pharmacokinetics and bioavailability.

Straub AM, Suvan J, Lang NP, Mombelli A, Braman V, Massaro J, Friden P, Tonetti MS.

J Periodontal Res. 2001 Jun;36(3):187-93.

PMID:
11453118
16.

Clinical and microbial evaluation of a histatin-containing mouthrinse in humans with experimental gingivitis.

Mickels N, McManus C, Massaro J, Friden P, Braman V, D'Agostino R, Oppenheim F, Warbington M, Dibart S, Van Dyke T.

J Clin Periodontol. 2001 May;28(5):404-10.

PMID:
11350502
17.

Sustained release of silver from periodontal wafers for treatment of periodontitis.

Bromberg LE, Braman VM, Rothstein DM, Spacciapoli P, O'Connor SM, Nelson EJ, Buxton DK, Tonetti MS, Friden PM.

J Control Release. 2000 Jul 31;68(1):63-72.

PMID:
10884580
18.

Combination chemotherapy followed by an immunotoxin (anti-B4-blocked ricin) in patients with indolent lymphoma: results of a phase II study.

Longo DL, Duffey PL, Gribben JG, Jaffe ES, Curti BD, Gause BL, Janik JE, Braman VM, Esseltine D, Wilson WH, Kaufman D, Wittes RE, Nadler LM, Urba WJ.

Cancer J. 2000 May-Jun;6(3):146-50.

PMID:
10882329
19.

Use of the immunotoxin N901-blocked ricin in patients with small-cell lung cancer.

Epstein C, Lynch T, Shefner J, Wen P, Maxted D, Braman V, Ariniello P, Coral F, Ritz J.

Int J Cancer Suppl. 1994;8:57-9.

PMID:
7515030
20.
21.
22.

Production of continuous mouse plasma cell lines by transfection with human leukemia DNA.

Jonak ZL, Braman V, Kennett RH.

Hybridoma. 1984 Summer;3(2):107-18.

PMID:
6592140

Supplemental Content

Loading ...
Support Center